Apart from local spread, the disease becomes disseminated by the lymphatic and venous routes. Though pathological studies indicate that the former may be commoner and early, most symptoms are due to blood-borne deposits. Involvement of adjacent bones and particularly the lumbar vertebrae is explicable by the distribution of the venous channels draining the periprostatic venous plexus, while distal involvement of the skeleton and soft structures is due to tumour emboli. Local lymphatic spread often remains concealed for a long period owing to the fact that the regional lymph nodes are deeply placed in the pelvis but serious obstruction may ultimately ensue and cause oedema of the feet. Occasionally superficial lymph node involvement may occur as the result of retrograde spread of lymphatic embolism.
Though no structures are exempt, most of the clinical features of the metastatic disease are related to bone involvement. Among these, pain (due to the extension of secondary deposits and the reactive process which surrounds them) is the main symptom. Less It is convenient to consider endocrine control therapy in two stages.
Initial Treatment
The initial choice lies between oestrogen therapy and castration, either of which can cause comparable symptomatic relief.
Castration is a definitive procedure which acts by depriving the patient of his main depots of androgen production.
Infertility is an inescapable sequel, but apart from this there are no side-effects except for a sense of genital inferioritywhich can be offset by the performance of a subcapsular orchidectomy to give a better cosmetic result. This operation is particularly suited to patients who are unable to sustain treatment with oestrogens either through intolerance, mental incapacity, or medical contraindications. In other circumstances supplementary oestrogen therapy may also be given, and some statistical evidence suggests that a combination may extend the duration of the response in patients with widespread metastatic disease.
Oestrogen therapy aims at the general suppression of androgen production by the testes and possibly at the site of action. Conceivably also some of the synthetic preparations currently used may act directly on the tumour cells. Histological changes in the prostatic epithelium may be noted within forty-eight hours of starting treatment.
In addition to genital shrinkage and a decline in libido various side-effects may ensue. Though many of these are of a minor feminizing character-such as change of complexion, loss of facial hair, and swelling of the breasts-they may nevertheless -prove obnoxious to a fastidious patient. Mammary enlargement can be prevented by a preliminary course of local x-ray therapy but this must be applied before starting treatment if it is to be effective.
Of more serious concern is that oestrogen administration inevitably leads to some measure of salt and water retention. In most cases this causes little disturbance beyond perhaps a slight "illusory" gain in weight but caution is required in patients with incipient cardiac failure. Diuretics to reduce the fluid load may possibly precipitate urinary difficulty if any significant obstruction remains at the primary site. The suggestion that oestrogen therapy predisposes to thrombosis has, as in the case of the pill, to be viewed in perspective and equated with the merits of such treatment. There is at present little indication that, in relation to age, any significant increase in mortality from this cause is likely, and if applied judiciously there can be no doubt that the benefits far outweigh the potential risks. Here the oestrogen component is of the natural variety, and possibly less effective, but good results have been achieved, particularly in cases with metastatic disease. The main drawbacks of depot therapy are that the absorption rate may be extremely variable and that when once the dose has been delivered it cannot readily be retrieved. Hence caution is thus required to avoid "water logging" in patients with cardiovascular disease.
Chlorotrianisine (T.A.C.E.) has been recommended from animal studies, which indicate that this substance may prevent compensatory adrenal hyperplasia (and hence the possibility of supplementary androgen production) known to follow castration. Clinical-experience, however, casts some doubt on its efficacy as an oestrogen compared with stilboestrol, and the additional claim that mammary- 
